23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › BLUEPRINT MEDICINES CORP. › 2023-2024

BLUEPRINT MEDICINES CORP. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 7Reported items
  • 313Asset managers, any item
  • 3,461Fund votes
  • June 12, 2024Meeting date

Results at a glance

Meeting of June 12, 2024: 6 items on BLUEPRINT MEDICINES CORP.’s Form 8-K, filed June 14, 2024: 3 approved · 3 passed (calculated).

Dissent

Significant dissent: 2 directors (30.0%, 26.7% against).

Notable dissent: 1 other board item (28.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore BLUEPRINT MEDICINES CORP. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by BLUEPRINT MEDICINES CORP.

These tallies are BLUEPRINT MEDICINES CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BLUEPRINT MEDICINES CORP. — official shareholder meeting results, meeting held June 12, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Daniella Beckman 54,014,668---- 4,259,5612,067,113 93%Passed (calculated)—
Elect Director: Habib Dable 40,783,723---- 17,490,5062,067,113 70%Passed (calculated)—
Elect Director: Lynn Seely, M.D. 42,706,299---- 15,567,9302,067,113 73%Passed (calculated)—
3. Non-binding, advisory vote on the compensation paid to its named executive officers 56,844,8791,345,31384,037 --2,067,113 98%Approved—
4. Company's stockholders approved the 2024 Plan. 41,494,78416,766,68412,761 --2,067,113 71%Approved—
5. Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2024. 60,124,981198,31718,044 ---- 99.7%Approved—

Source: BLUEPRINT MEDICINES CORP., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.

How asset managers voted at the BLUEPRINT MEDICINES CORP. 2023-2024 meeting

313 asset managers disclosed a vote on at least one BLUEPRINT MEDICINES CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BLUEPRINT MEDICINES CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Daniella Beckman

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 54,014,668WITHHELD: 4,259,561
Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: Election of Directors: Daniella Beckman

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Daniella Beckman”): 54,014,668 for, 4,259,561 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 32,378,609 for, 1,642,250 withheld, 415,871 abstained.

FOR
FOR: 32,378,609ABSTAIN: 415,871WITHHOLD: 1,642,250
Largest asset managers voting on “Election of Directors: Daniella Beckman” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity5,991,2530 013,266For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett1,145,4200 00For
Delaware/Macquarie945,1660 00For
State Street821,8350 088For
JPMorgan724,7260 00For
American Century519,4670 00For
Charles Schwab00 0502,210Withhold
Invesco430,4630 00For
AllianceBernstein00 0428,993Withhold
WILLIAM BLAIR FUNDS350,9240 00For
Principal77,2070 0199,517Mixed
Equitable120,2840 0141,539Mixed
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National221,7710 00For
Manager Directed Portfolios00 212,3140Abstain
AB DISCOVERY GROWTH FUND, INC.00 0202,784Withhold
Brown Advisory Funds201,8020 00For
John Hancock162,9810 31,0190Mixed
Goldman Sachs178,0550 00For
FINANCIAL INVESTORS TRUST00 166,5700Abstain

Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).

Elect Director: Habib Dable

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

70% Majority: yes · of votes cast

FOR 70%WITHHELD
FOR: 40,783,723WITHHELD: 17,490,506
Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: Election of Directors: Habib Dable

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Habib Dable”): 40,783,723 for, 17,490,506 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 70% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 26,810,163 for, 33 against, 6,786,022 withheld, 840,512 abstained.

FORWITHHOLD
FOR: 26,810,163AGAINST: 33ABSTAIN: 840,512WITHHOLD: 6,786,022
Largest asset managers voting on “Election of Directors: Habib Dable” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity5,991,2530 013,266For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett00 01,145,420Withhold
Delaware/Macquarie00 0945,166Withhold
State Street8700 0821,053Withhold
JPMorgan724,7260 00For
American Century00 0519,467Withhold
Charles Schwab502,2100 00For
Invesco00 0430,463Withhold
AllianceBernstein00 0428,993Withhold
WILLIAM BLAIR FUNDS00 0350,924Withhold
Principal4580 0276,266Withhold
Equitable120,2840 0141,539Mixed
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National00 221,7710Abstain
Manager Directed Portfolios212,3140 00For
AB DISCOVERY GROWTH FUND, INC.00 0202,784Withhold
Brown Advisory Funds00 201,8020Abstain
John Hancock109,5820 84,4180Mixed
Goldman Sachs00 0178,055Withhold
FINANCIAL INVESTORS TRUST00 166,5700Abstain

Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).

Elect Director: Lynn Seely, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%WITHHELD
FOR: 42,706,299WITHHELD: 15,567,930
Details: description as filed, official tally, votes by 101 asset managers

Description as filed by funds: Election of Directors: Lynn Seely

BLUEPRINT MEDICINES CORP.’s own tally for this item (“Elect Director: Lynn Seely, M.D.”): 42,706,299 for, 15,567,930 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 101 asset managers below reported 27,682,317 for, 33 against, 5,912,404 withheld, 841,976 abstained.

FORWITHHOLD
FOR: 27,682,317AGAINST: 33ABSTAIN: 841,976WITHHOLD: 5,912,404
Largest asset managers voting on “Election of Directors: Lynn Seely” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity5,991,2530 013,266For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett00 01,145,420Withhold
Delaware/Macquarie00 0945,166Withhold
State Street820,7740 01,149For
JPMorgan724,7260 00For
American Century00 0519,467Withhold
Charles Schwab502,2100 00For
Invesco00 0430,463Withhold
AllianceBernstein00 0428,993Withhold
WILLIAM BLAIR FUNDS00 0350,924Withhold
Principal4580 0276,266Withhold
Equitable120,2840 0141,539Mixed
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National00 221,7710Abstain
Manager Directed Portfolios212,3140 00For
AB DISCOVERY GROWTH FUND, INC.00 0202,784Withhold
Brown Advisory Funds00 201,8020Abstain
John Hancock109,5820 84,4180Mixed
Goldman Sachs00 0178,055Withhold
FINANCIAL INVESTORS TRUST00 166,5700Abstain

Showing the 25 largest of 101 asset managers. All 101 are in the interactive database (link above).

4. The Company's stockholders approved the 2024 Plan.

Official resultCOMPENSATIONReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

71% Approved · of votes cast

FOR 71%AGAINST
FOR: 41,494,784AGAINST: 16,766,684
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: APPROVAL OF THE BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“4. The Company's stockholders approved the 2024 Plan.”): 41,494,784 for, 16,766,684 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the 2024 Plan.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 27,872,885 for, 6,540,409 against.

FORAGAINST
FOR: 27,872,885AGAINST: 6,540,409
Largest asset managers voting on “APPROVAL OF THE BLUEPRINT MEDICINES CORPORATION 2024 STOCK INCENTIVE PLAN.” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity6,004,5190 00For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett01,145,420 00Against
Delaware/Macquarie0945,166 00Against
State Street870821,053 00Against
JPMorgan724,7260 00For
American Century0519,467 00Against
Charles Schwab502,2100 00For
Invesco0430,463 00Against
AllianceBernstein428,9930 00For
WILLIAM BLAIR FUNDS0350,924 00Against
Principal199,97576,749 00Mixed
Equitable261,8230 00For
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National0221,771 00Against
Manager Directed Portfolios212,3140 00For
AB DISCOVERY GROWTH FUND, INC.202,7840 00For
Brown Advisory Funds0201,802 00Against
John Hancock109,58284,418 00Mixed
Goldman Sachs0178,055 00Against
FINANCIAL INVESTORS TRUST166,5700 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Non-binding, advisory vote on the compensation paid to its named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 56,844,879AGAINST: 1,345,313

Prior year: 98.2% for (June 21, 2023 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 305 asset managers

Description as filed by funds: APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“3. The non-binding, advisory vote on the compensation paid to its named executive officers”): 56,844,879 for, 1,345,313 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 101 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity6,004,5190 00For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett1,145,4200 00For
Delaware/Macquarie945,1660 00For
State Street821,9230 00For
JPMorgan724,7260 00For
American Century519,4670 00For
Charles Schwab502,2100 00For
Invesco0430,463 00Against
AllianceBernstein428,9930 00For
WILLIAM BLAIR FUNDS350,9240 00For
Principal276,7240 00For
Equitable261,8230 00For
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National121,85599,916 00Mixed
Manager Directed Portfolios212,3140 00For
AB DISCOVERY GROWTH FUND, INC.202,7840 00For
Brown Advisory Funds201,8020 00For
John Hancock194,0000 00For
Goldman Sachs178,0550 00For
FINANCIAL INVESTORS TRUST166,5700 00For

Fund voting reports, all 101 managers: 33,688,111 for, 709,708 against, 17,858 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 236 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price7,008,5240 00For
Fidelity5,126,0160 00For
Wellington3,861,2870 00For
Man Group plc3,000,5500 00For
Rock Springs Capital Management LP2,498,4490 00For
BlackRock2,115,6870 00For
New York Life2,000,0000 00For
State Street1,984,6310 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC1,472,5440 00For
GEODE CAPITAL MANAGEMENT, LLC1,351,6610 00For
PICTET ASSET MANAGEMENT SA1,316,8630 00For
LORD, ABBETT & CO. LLC1,240,6960 00For
JPMorgan1,159,3650 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST1,143,7600 00For
AllianceBernstein1,085,6240 00For
Woodline Partners LP909,9100 00For
Polar Capital Holdings Plc865,0000 00For
BROWN ADVISORY INC566,4540 00For
American Century543,2160 00For
Charles Schwab522,9180 00For
Northern Trust521,42242 00For
Invesco0514,385 00Against
Holocene Advisors, LP492,9160 00For
Ensign Peak Advisors, Inc463,7690 00For
Hood River Capital Management LLC418,4040 00For

Institutional-manager reports, all 236 managers: 47,456,755 for, 928,472 against, 52,063 abstained, 765 not voted, 33,655 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Approval of a non-binding advisory vote on the frequency of future advisory votes on the compensation paid to our named…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 296 asset managers

Description as filed by funds: APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 98 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO ” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
Fidelity00 00--
T. Rowe Price00 00--
BlackRock00 00--
Lord Abbett00 00--
Delaware/Macquarie00 00--
State Street00 00--
JPMorgan00 00--
American Century00 00--
Charles Schwab00 00--
Invesco00 00--
AllianceBernstein00 00--
WILLIAM BLAIR FUNDS00 00--
Principal00 00--
Equitable00 00--
TIAA00 00--
Hartford00 00--
Jackson National00 00--
Manager Directed Portfolios00 00--
AB DISCOVERY GROWTH FUND, INC.00 00--
Brown Advisory Funds00 00--
John Hancock00 00--
Goldman Sachs00 00--
FINANCIAL INVESTORS TRUST00 00--
Brighthouse00 00--

Fund voting reports, all 98 managers: 3,907 for, 17,858 abstained, 34,072,011 1 year, 47,772 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 230 asset managers voting on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES ON THE COMPENSATION PAID TO ” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price00 00--
Fidelity00 00--
Wellington00 00--
Man Group plc00 00--
Rock Springs Capital Management LP00 00--
BlackRock00 00--
New York Life00 00--
State Street00 00--
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
PICTET ASSET MANAGEMENT SA00 00--
LORD, ABBETT & CO. LLC00 00--
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST00 00--
AllianceBernstein00 00--
Woodline Partners LP00 00--
Polar Capital Holdings Plc00 00--
BROWN ADVISORY INC00 00--
American Century00 00--
Charles Schwab00 00Not Voted
Northern Trust00 00--
Invesco00 00--
Holocene Advisors, LP00 00--
Ensign Peak Advisors, Inc00 00--
Hood River Capital Management LLC418,4040 00For
MELLON INVESTMENTS Corp00 00--

Institutional-manager reports, all 230 managers: 587,775 for, 765 not voted, 46,205,740 1 year, 597,863 3 year, 4,636 2 year. Showing the 25 largest; every one is in the interactive database (link above).

5. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.7% Approved · of votes cast

FOR 99.7%
FOR: 60,124,981AGAINST: 198,317
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

BLUEPRINT MEDICINES CORP.’s own tally for this item (“5. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2024.”): 60,124,981 for, 198,317 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2024.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 34,419,242 for, 349 against, 17,858 abstained.

FOR
FOR: 34,419,242AGAINST: 349ABSTAIN: 17,858
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR ” at BLUEPRINT MEDICINES CORP., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard8,825,3440 00For
Fidelity6,004,5190 00For
T. Rowe Price5,448,3220 00For
BlackRock3,279,2220 00For
Lord Abbett1,145,4200 00For
Delaware/Macquarie945,1660 00For
State Street821,787136 00For
JPMorgan724,7260 00For
American Century519,4670 00For
Charles Schwab502,2100 00For
Invesco430,4630 00For
AllianceBernstein428,9930 00For
WILLIAM BLAIR FUNDS350,9240 00For
Principal276,7240 00For
Equitable261,8230 00For
TIAA261,5250 00For
MUTUAL FUND SERIES TRUST231,6850 00For
Hartford222,8840 00For
Jackson National221,7710 00For
Manager Directed Portfolios212,3140 00For
AB DISCOVERY GROWTH FUND, INC.202,7840 00For
Brown Advisory Funds201,8020 00For
John Hancock194,0000 00For
Goldman Sachs178,0550 00For
FINANCIAL INVESTORS TRUST166,5700 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Largest BLUEPRINT MEDICINES CORP. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 62,616,902 shares outstanding at the time of that meeting.

Fund voting reports: top BLUEPRINT MEDICINES CORP. shareholders by shares voted on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 14.09%
2Fidelity 9.59%
3T. Rowe Price 8.70%
4BlackRock 5.24%
5Lord Abbett 1.83%
6Delaware/Macquarie 1.51%
7State Street 1.31%
8JPMorgan 1.16%
9American Century 0.83%
10Charles Schwab 0.80%
Institutional-manager reports: top BLUEPRINT MEDICINES CORP. shareholders by shares voted on “APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE…”, 2023-2024
#Asset manager % of shares outstanding
1T. Rowe Price 11.19%
2Fidelity 8.19%
3Wellington 6.17%
4Man Group plc 4.79%
5Rock Springs Capital Management LP 3.99%
6BlackRock 3.38%
7New York Life 3.19%
8State Street 3.17%
9WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.35%
10GEODE CAPITAL MANAGEMENT, LLC 2.16%

Reported BLUEPRINT MEDICINES CORP. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BLUEPRINT MEDICINES CORP. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
T. Rowe Price6,250,823 9.98%Form 13F, quarter ended March 31, 2024
The Vanguard Group6,114,970 9.77%Schedule 13G, filed January 10, 2024
Wellington Management4,175,152 6.67%Form 13F, quarter ended March 31, 2024
State Street2,192,702 3.50%Form 13F, quarter ended March 31, 2024
Geode Capital1,371,127 2.19%Form 13F, quarter ended March 31, 2024
Invesco809,600 1.29%Form 13F, quarter ended March 31, 2024
Norges Bank560,792 0.90%Form 13F, quarter ended March 31, 2024
Northern Trust558,890 0.89%Form 13F, quarter ended March 31, 2024
Charles Schwab501,135 0.80%Form 13F, quarter ended March 31, 2024
D.E. Shaw383,477 0.61%Form 13F, quarter ended March 31, 2024

Percentages above are of 62,616,902 shares outstanding, as reported by BLUEPRINT MEDICINES CORP. on its Form 10-Q dated April 30, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BLUEPRINT MEDICINES CORP.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 313 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 3,461 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL OF A NON-BINDING ADVISORY VOTE ON THE COMPENSATION PAID TO OUR NAMED EXECUTIVE… — BLUEPRINT MEDICINES CORP.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BLUEPRINT MEDICINES CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BLUEPRINT MEDICINES CORP.’s 10-Q dated April 30, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BLUEPRINT MEDICINES CORP. proxy season coverage: 2023-2024 (this page) · 2024-2025.

Cite this page

Proxy Votes Now, “BLUEPRINT MEDICINES CORP. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/blueprint-medicines-corp/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.